A fruitful collaboration between Sprint Bioscience (SME) & Dr. Bassam Janji (Academic Researcher)

The Tumor Immunotherapy and Microenvironment (TIME) group led by Dr. Bassam Janji at Luxembourg Institute of Health has previously identified autophagy as a resistance mechanism protecting cancer cells from immune surveillance. Sprint Bioscience, a Swedish drug discovery company has developed a selective Vps34 inhibitor (SB02024) with an excellent pharmacological profile. Following discussion during the Annual TRANSAUTOPHAGY Conference, held in Warsaw Poland, October 2016, Bassam Janji and Sprint Bioscience started a collaboration bridging together their respective competencies in tumor immunology, autophagy and drug development to investigate the impact of Vps34 inhibition on the improvement of the therapeutic benefit of immunotherapy.

Click here for more information.

Post comment

Your email address will not be published. Required fields are marked *

© Transautophagy